X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA DR. DATSONS LABS SHASUN PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 123.9 -10.9 - View Chart
P/BV x 8.5 0.2 5,255.6% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
SHASUN PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs94126 75.0%   
Low Rs4631 147.6%   
Sales per share (Unadj.) Rs214.2133.0 161.0%  
Earnings per share (Unadj.) Rs5.30.2 3,519.5%  
Cash flow per share (Unadj.) Rs15.86.6 239.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.3128.8 41.4%  
Shares outstanding (eoy) m56.6231.66 178.8%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x0.30.6 55.5%   
Avg P/E ratio x13.1516.1 2.5%  
P/CF ratio (eoy) x4.411.8 37.3%  
Price / Book Value ratio x1.30.6 215.7%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9582,477 159.8%   
No. of employees `000NANA-   
Total wages/salary Rs m2,16456 3,863.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m12,1274,211 288.0%  
Other income Rs m22979 291.4%   
Total revenues Rs m12,3564,289 288.1%   
Gross profit Rs m1,009569 177.5%  
Depreciation Rs m594204 290.4%   
Interest Rs m415430 96.5%   
Profit before tax Rs m23013 1,808.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 16.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-736 -1,192.1%   
Profit after tax Rs m3025 6,294.2%  
Gross profit margin %8.313.5 61.6%  
Effective tax rate %-31.748.0 -65.9%   
Net profit margin %2.50.1 2,185.4%  
BALANCE SHEET DATA
Current assets Rs m6,8846,852 100.5%   
Current liabilities Rs m8,4566,711 126.0%   
Net working cap to sales %-13.03.3 -387.0%  
Current ratio x0.81.0 79.7%  
Inventory Days Days62161 38.3%  
Debtors Days Days108318 33.8%  
Net fixed assets Rs m4,9703,673 135.3%   
Share capital Rs m113317 35.8%   
"Free" reserves Rs m2,8753,761 76.4%   
Net worth Rs m3,0204,078 74.1%   
Long term debt Rs m1,8171,671 108.8%   
Total assets Rs m13,34712,633 105.7%  
Interest coverage x1.61.0 150.9%   
Debt to equity ratio x0.60.4 146.9%  
Sales to assets ratio x0.90.3 272.6%   
Return on assets %5.43.4 156.1%  
Return on equity %10.00.1 8,497.6%  
Return on capital %13.37.7 173.6%  
Exports to sales %46.422.9 202.5%   
Imports to sales %14.214.3 99.7%   
Exports (fob) Rs m5,622964 583.1%   
Imports (cif) Rs m1,728602 287.0%   
Fx inflow Rs m5,843964 606.1%   
Fx outflow Rs m2,173607 358.0%   
Net fx Rs m3,669357 1,028.2%   
CASH FLOW
From Operations Rs m3981,345 29.6%  
From Investments Rs m-1,635-2,256 72.5%  
From Financial Activity Rs m1,309-1,200 -109.1%  
Net Cashflow Rs m71-2,111 -3.4%  

Share Holding

Indian Promoters % 39.2 4.5 865.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.0 -  
FIIs % 17.6 1.4 1,303.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 94.1 42.1%  
Shareholders   20,750 20,807 99.7%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS